{"id":"elgn-2112","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":{"chemblId":"CHEMBL5985993","moleculeType":null,"molecularWeight":"477.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, ELGN-2112 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"ELGN-2112 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:39.876Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05670951","phase":"PHASE3","title":"Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants","status":"RECRUITING","sponsor":"Elgan Pharma Ltd.","startDate":"2025-02-27","conditions":"Intestinal Malabsorption","enrollment":360},{"nctId":"NCT05904626","phase":"PHASE2","title":"Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA","status":"NOT_YET_RECRUITING","sponsor":"Elgan Pharma Ltd.","startDate":"2025-09","conditions":"Intestinal Malabsorption","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ELGN-2112","genericName":"ELGN-2112","companyName":"Elgan Pharma Ltd.","companyId":"elgan-pharma-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ELGN-2112 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}